



NDA 50420/S-077  
NDA 50627/S-020

## SUPPLEMENT APPROVAL

Sanofi-aventis U.S. LLC  
Attention: John Cook,  
Senior Director, Global Regulatory Affairs  
55 Corporate Drive; Mailstop: 55C-205A  
Bridgewater, NJ 08807

Dear Mr. Cook:

Please refer to your Supplemental New Drug Applications (sNDAs) dated August 3, 2017, received August 3, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for RIFADIN (rifampin USP) Capsules USP 300 mg [NDA 50420] and RIFADIN IV (rifampin) Intravenous USP 600 mg [NDA 50627] .

This “Changes Being Effected” supplemental new drug application provides for

A revision of the **PRECAUTIONS** and **ADVERSE REACTIONS** sections to add teeth discoloration.

### **APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mr. Gregory DiBernardo, Regulatory Project Manager, at (301) 796-4063.

Sincerely,

*{See appended electronic signature page}*

Joseph G. Toerner, M.D., M.P.H.  
Deputy Director for Safety  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling